| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Center for Allergy, Asthma, and Immunology, Creighton University School of Medicine, Omaha, NE 68178
Pretreatment with mycobacterial Ags has been shown to be effective in preventing allergic airway inflammation from occurring in a mouse model. Because most asthmatics are treated after the development of asthma, it is crucial to determine whether mycobacterial Ags can reverse established allergic airway inflammation in the presensitized state. Our hypothesis, based upon our previous findings, is that mycobacteria treatment in presensitized mice will suppress the allergic airway inflammation with associated clinical correlates of established asthma, with the noted exception of factors associated with the early allergic response (EAR). BALB/c mice sensitized and challenged with OVA were evaluated for pulmonary functions during both the EAR and late allergic response, and airway hyperresponsiveness to methacholine. Following this, sensitized mice were randomized and treated with placebo or a single dose (1 x 105 CFUs) of bacillus Calmette-Guérin (BCG) or Mycobacterium vaccae via nasal or peritoneal injection. One week later, the mice were rechallenged with OVA and methacholine, followed by bronchoalveolar lavage (BAL) and tissue collection. Mice treated with intranasal BCG were most significantly protected from the late allergic response (p < 0.02), airway hypersensitivity (p < 0.001) and hyperreactivity (p < 0.05) to methacholine, BAL (p < 0.05) and peribronchial (p < 0.01) eosinophilia, and BAL fluid IL-5 levels (p < 0.01) as compared with vehicle-treated, sensitized controls. Intranasal M. vaccae treatment was less effective, suppressing airway hypersensitivity (p < 0.01) and BAL eosinophilia (p < 0.05). No changes were observed in the EAR, BAL fluid IL-4 levels, or serum total and Ag-specific IgE. These data suggest that mycobacterial Ags (BCG>>M. vaccae) are effective in attenuating allergic airway inflammation and associated changes in pulmonary functions in an allergen-presensitized state.
This article has been cited by other articles:
|
|
 |
|
  R. D. Balicer, I. Grotto, M. Mimouni, and D. Mimouni Is Childhood Vaccination Associated With Asthma? A Meta-analysis of Observational Studies Pediatrics, November 1, 2007; 120(5): e1269 - e1277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sugiura, X. Liu, F. Duan, S. Kawasaki, S. Togo, K. Kamio, X. Q. Wang, L. Mao, Y. Ahn, R. F. Ertl, et al. Cultured Lung Fibroblasts from Ovalbumin-Challenged "Asthmatic" Mice Differ Functionally from Normal Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 424 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Paveglio, J. Allard, J. Mayette, L. A. Whittaker, I. Juncadella, J. Anguita, and M. E. Poynter The Tick Salivary Protein, Salp15, Inhibits the Development of Experimental Asthma J. Immunol., June 1, 2007; 178(11): 7064 - 7071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Moisan, P. Camateros, T. Thuraisingam, D. Marion, H. Koohsari, P. Martin, M. L. Boghdady, A. Ding, M. Gaestel, M. C. Guiot, et al. TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L987 - L995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Leino, H. T. Alenius, N. Fyhrquist-Vanni, H. J. Wolff, K. E. Reijula, E.-L. Hintikka, M. S. Salkinoja-Salonen, T. Haahtela, and M. J. Makela Intranasal Exposure to Stachybotrys chartarum Enhances Airway Inflammation in Allergic Mice Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 512 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Peters, M Kauth, J Schwarze, C Korner-Rettberg, J Riedler, D Nowak, C Braun-Fahrlander, E von Mutius, A Bufe, O Holst, et al. Inhalation of stable dust extract prevents allergen induced airway inflammation and hyperresponsiveness Thorax, February 1, 2006; 61(2): 134 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Edwan, G. Perry, J. E. Talmadge, and D. K. Agrawal Flt-3 Ligand Reverses Late Allergic Response and Airway Hyper-Responsiveness in a Mouse Model of Allergic Inflammation J. Immunol., April 15, 2004; 172(8): 5016 - 5023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Primm, C. A. Lucero, and J. O. Falkinham III Health Impacts of Environmental Mycobacteria Clin. Microbiol. Rev., January 1, 2004; 17(1): 98 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Smit, H. Van Loveren, M. O. Hoekstra, K. Karimi, G. Folkerts, and F. P. Nijkamp The Slc11a1 (Nramp1) Gene Controls Efficacy of Mycobacterial Treatment of Allergic Asthma J. Immunol., July 15, 2003; 171(2): 754 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Camporota, A. Corkhill, H. Long, J. Lordan, L. Stanciu, N. Tuckwell, A. Cross, J.L. Stanford, G.A.W. Rook, S.T. Holgate, et al. The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma Eur. Respir. J., February 1, 2003; 21(2): 287 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zuany-Amorim, C. Manlius, A. Trifilieff, L. R. Brunet, G. Rook, G. Bowen, G. Pay, and C. Walker Long-Term Protective and Antigen-Specific Effect of Heat-Killed Mycobacterium vaccae in a Murine Model of Allergic Pulmonary Inflammation J. Immunol., August 1, 2002; 169(3): 1492 - 1499. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
